Premium
Central administration of GPR 55 receptor agonist and antagonist modulates anxiety‐related behaviors in rats
Author(s) -
Rahimi Abbasali,
Hajizadeh Moghaddam Akbar,
Roohbakhsh Ali
Publication year - 2015
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/fcp.12099
Subject(s) - agonist , anxiolytic , antagonist , cannabinoid receptor , cannabinoid , receptor , endocrinology , pharmacology , chemistry , receptor antagonist , medicine , inverse agonist , anxiety , psychiatry
G‐protein‐coupled receptor 55 ( GPR 55) has been proposed as an atypical cannabinoid receptor, which is activated by lysophosphatidylinositols and some synthetic or endogenous cannabinoid molecules. The exact role of GPR 55 receptors in the central nervous system especially in anxiety needs to be evaluated. In this study, the effects of intracerebroventricular (i.c.v.) administration of agonist and antagonist of GPR 55 receptor on anxiety‐related behaviors in rats were investigated. Here, O‐1602 ( GPR 55 agonist) at the doses of 0.2, 1, and 5 μg/rat increased % OAT and % OAE but not the locomotor activity, showing an anxiolytic response, whereas i.c.v. injection of ML 193 ( GPR 55 antagonist) at the doses of 0.1 and 1 μg/rat increased anxiety‐like behaviors while causing locomotor impairment. The antagonistic effect of ML 193 on the anxiolytic‐like effect of O‐1602 was also evaluated. The results showed that ML 193 decreased the anxiolytic‐like effect of O‐1602. Based on these results, it may be concluded that central GPR 55 may have a role in modulation of anxiety‐like behaviors in rats. Further experiments are needed to elucidate the exact role of these receptors in anxiety.